GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Central Pharmaceuticals Ltd (DHA:CENTRALPHL) » Definitions » Cash Flow from Operations

Central Pharmaceuticals (DHA:CENTRALPHL) Cash Flow from Operations : BDT-1.12 Mil (TTM As of Sep. 2022)


View and export this data going back to 2013. Start your Free Trial

What is Central Pharmaceuticals Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Sep. 2022, Central Pharmaceuticals's Cash Receipts from Operating Activities was BDT6.42 Mil. Its Cash Payments was BDT-6.41 Mil. Its Dividends Paid was BDT0.00 Mil. Its Dividends Received was BDT0.00 Mil. Its Interest Paid was BDT0.00 Mil. Its Interest Received was BDT0.00 Mil. Its Taxes Refund Paid was BDT0.00 Mil. And its Cash Flow from Others was BDT-0.00 Mil. In all, Central Pharmaceuticals's Cash Flow from Operations for the three months ended in Sep. 2022 was BDT0.01 Mil.


Central Pharmaceuticals Cash Flow from Operations Historical Data

The historical data trend for Central Pharmaceuticals's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Central Pharmaceuticals Cash Flow from Operations Chart

Central Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.33 -0.41 1.80 -1.12 -0.33

Central Pharmaceuticals Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Jun23
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 0.20 -1.25 0.01 -

Central Pharmaceuticals Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Central Pharmaceuticals's Cash Flow from Operations for the fiscal year that ended in Jun. 2023 is calculated as:

Central Pharmaceuticals's Cash Flow from Operations for the quarter that ended in Sep. 2022 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-1.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Central Pharmaceuticals  (DHA:CENTRALPHL) Cash Flow from Operations Explanation

For non-financial companies reported in direct method, cash flow from operations contains eight items:

1. Cash Receipts from Operating Activities:
Cash Receipts from Operating Activities represents cash received from operating activitiies in direct method.

Central Pharmaceuticals's cash receipts from operating activities for the three months ended in Sep. 2022 was BDT6.42 Mil.

2. Cash Payments:
It represents cash flow paid from operating activities in the direct cash flow method.

Central Pharmaceuticals's cash payments for the three months ended in Sep. 2022 was BDT-6.41 Mil.

3. Dividends Paid:
It represents dividend paid to the investors in the direct cash flow method.

Central Pharmaceuticals's cash payments for the three months ended in Sep. 2022 was BDT0.00 Mil.

4. Dividends Received:
It represents dividend received on the investment in the direct cash flow method.

Central Pharmaceuticals's cash payments for the three months ended in Sep. 2022 was BDT0.00 Mil.

5. Interest Paid:
It represents interest paid on loans, debt or borrowings, in the direct cash flow method.

Central Pharmaceuticals's cash payments for the three months ended in Sep. 2022 was BDT0.00 Mil.

6. Interest Received:
It represents interest received by the company in the direct cash flow method.

Central Pharmaceuticals's cash payments for the three months ended in Sep. 2022 was BDT0.00 Mil.

7. Taxes Refund Paid:
It represents tax paid or refund related to operating activities in the direct cash flow method.

Central Pharmaceuticals's cash payments for the three months ended in Sep. 2022 was BDT0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of cash receipts and cash payments. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its cash position will grow more slowly (or even shrink).

Central Pharmaceuticals's cash flow from others for the three months ended in Sep. 2022 was BDT-0.00 Mil.


Central Pharmaceuticals Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Central Pharmaceuticals's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Central Pharmaceuticals (DHA:CENTRALPHL) Business Description

Traded in Other Exchanges
N/A
Address
South West Darus Salam Road, 2-A/1, 2nd Floor, Mirpur - 1, Dhaka, BGD, 1216
Central Pharmaceuticals Ltd is engaged in the manufacturing and marketing of medicines in Bangladesh. The company manufactures finished formulation products for general people, hospitals, clinics, government organizations, corporations, and other non-government organizations. Its product portfolio encompasses therapeutic categories including gastrointestinal, anti-infective, vitamins and minerals, allergy cough and cold, analgesic and musculoskeletal, dermatological, oral rehydration salt, and others. The products are in the dosage forms of tablets, capsules, liquid, and ointments.

Central Pharmaceuticals (DHA:CENTRALPHL) Headlines

No Headlines